You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,007,826


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,007,826
Title:Sustained release aminopyridine composition
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Inventor(s): Blight; Andrew R. (Mahopac, NY), Cohen; Ron (Irvington, NY)
Assignee: Acorda Therapeutics, Inc. (Hawthorne, NY)
Application Number:11/010,828
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,007,826
Patent Claims: 1. A method for maintaining a therapeutically effective concentration of 4-aminopyridine in order to improve walking in a human with multiple sclerosis in need thereof, said method comprising: orally administering to the human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a day; and thereafter, maintaining administration of 4-aminopyridine by orally administering to said human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of at least two weeks, whereby an in vivo 4-aminopyridine C.sub.maxSS:C.sub.minSS ratio of 1.0 to 3.5 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are obtained in the human.

2. The method of claim 1, whereby an increase in walking speed is obtained in said human.

3. The method of claim 1, whereby an improvement in lower extremity muscle strength is obtained in said human.

4. The method of claim 1, wherein the sustained release composition further comprises an additional active ingredient.

5. The method of claim 1, wherein the sustained release composition further comprises a pharmaceutically acceptable excipient.

6. A dosing regimen method for providing a 4-aminopyridine at a therapeutically effective concentration in order to improve walking in a human with multiple sclerosis in need thereof, said method comprising: initiating administration of 4-aminopyridine by orally administering to said human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a day without a prior period of 4-aminopyridine titration, and then, maintaining administration of 4-aminopyridine by orally administering to said human a sustained release composition of 10 milligrams of 4-aminopyridine twice daily; without a subsequent period of 4-aminopyridine titration, whereby an in vivo C.sub.maxSS:C.sub.minSS ratio of 1.0 to 3.5 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are maintained in the human.

7. The method of claim 6, whereby an increase in walking speed is obtained in said human.

8. The method of claim 6, whereby an improvement in lower extremity muscle strength is obtained in said human.

9. The method of claim 6, wherein the sustained release composition further comprises an additional active ingredient.

10. The method of claim 6, wherein the sustained release composition further comprises a pharmaceutically acceptable excipient.

11. A method for maintaining a therapeutically effective concentration of 4-aminopyridine in a human with multiple sclerosis in need of an improvement in walking, in order to improve walking in the human, said method comprising: orally administering twice daily to the human a sustained release composition comprising a pharmaceutically acceptable excipient and 4-aminopyridine, the 4-aminopyridine consisting of 10 milligrams of 4-aminopyridine, for one day; and thereafter, maintaining twice daily administration for a time period of greater than two weeks of a sustained release composition comprising a pharmaceutically acceptable excipient and 4-aminopyridine, the 4-aminopyridine consisting of 10 milligrams of 4-aminopyridine; whereby an in vivo 4-aminopyridine C.sub.maxSS:C.sub.minSS ratio of 1.0 to 3.5 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are obtained in the human.

12. The method of claim 11, wherein an improvement in lower extremity muscle strength is obtained in said human.

13. The method of claim 1, further comprising a step of determining the C.sub.maxSS:C.sub.minSS ratio or the C.sub.avSS.

14. The method of claim 11, wherein the twice daily administration comprises b.i.d. administration or administration at 12-hour intervals.

15. The method of claim 11, whereby an in vivo C.sub.maxSS:C.sub.minSS ratio of 1.5 to 3.0 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are obtained in the human.

16. The method of claim 11, whereby an in vivo C.sub.maxSS:C.sub.minSS ratio of 2.0 to 3.0 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are obtained in the human.

17. A method to improve walking by a human with multiple sclerosis in need thereof, said method comprising: orally administering twice daily for one day to the human a sustained release composition of 10 milligrams of 4-aminopyridine and an agent selected from the group consisting of one or more additional active ingredients, one or more pharmaceutically acceptable excipients and a combination thereof; and thereafter, maintaining twice daily administration of 4-aminopyridine by orally administering twice daily to said human a sustained release composition of 10 milligrams of 4-aminopyridine and an agent selected from the group consisting of one or more additional active ingredients, one or more pharmaceutically acceptable excipients and a combination thereof for a time period of greater than two weeks; whereby an in vivo 4-aminopyridine C.sub.maxSS:C.sub.minSS ratio of 1.0 to 3.5 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are obtained and there is an improvement in walking by the human.

18. The method of claim 1, whereby an in vivo C.sub.maxSS:C.sub.minSS ratio of 1.5 to 3.0 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are obtained in the human.

19. The method of claim 1, whereby an in vivo C.sub.maxSS:C.sub.minSS ratio of 2.0 to 3.0 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are obtained in the human.

20. The method of claim 1 wherein the maintaining step comprises maintaining for a period of more than two weeks.

21. The method of claim 1 wherein the maintaining step comprises maintaining for a period of more than twelve weeks.

22. The method of claim 1 wherein said sustained release composition is a tablet.

23. The method of claim 6 wherein the maintaining step comprises maintaining for a period of at least a week.

24. The method of claim 6 wherein the maintaining step comprises maintaining for a period of at least two weeks.

25. The method of claim 6 wherein the maintaining step comprises maintaining for a period of more than two weeks.

26. The method of claim 6 wherein the maintaining step comprises maintaining for a period of more than twelve weeks.

27. The method of claim 6, whereby an in vivo C.sub.maxSS:C.sub.minSS ratio of 1.5 to 3.0 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are obtained in the human.

28. The method of claim 6, whereby an in vivo C.sub.maxSS:C.sub.minSS ratio of 2.0 to 3.0 and a C.sub.avSS of 15 ng/ml to 35 ng/ml are obtained in the human.

29. The method of claim 6 wherein said sustained release composition is a tablet.

30. The method of claim 17 wherein said sustained release composition is a tablet.

31. A method of increasing walking speed in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of greater than two weeks, wherein said sustained release composition provides a mean T.sub.max in a range of about 1 to about 6 hours after administration of the sustained release composition to the patient.

32. The method of claim 31 wherein the sustained release composition elicits a C.sub.maxSS:C.sub.minSS ratio of 1.0 to 3.5 when administered b.i.d. or administered at 12-hour intervals to a human.

33. The method of claim 31 wherein said time period is twelve weeks.

34. The method of claim 31 wherein said sustained release composition is a tablet.

35. The method of claim 31 wherein the step of administering comprises b.i.d. administering or administering at 12-hour intervals.

36. A method to improve walking in a patient with multiple sclerosis in need thereof by use of a sustained release composition of 4-aminopyridine, where sustained indicates that the composition achieves an in vivo 4-aminopyridine C.sub.maxSS:C.sub.minSS ratio of 1.0 to 3.5 and a C.sub.avSS of 15 ng/ml to 35 ng/ml in a human, said method comprising: orally administering twice daily for one day to the patient an amount of the sustained release composition having only 10 milligrams of 4-aminopyridine; and thereafter, maintaining twice daily administration of 4-aminopyridine by orally administering to said patient an amount of the sustained release composition having only 10 milligrams of 4-aminopyridine for a time period of at least two weeks.

37. A method of increasing walking speed in a human multiple sclerosis patient in need thereof comprising orally administering to said patient a sustained release composition of 10 milligrams of 4-aminopyridine twice daily for a time period of greater than two weeks, wherein said sustained release composition provides a mean T.sub.max in a range of about 2 to about 5.2 hours after administration of the sustained release composition to the patient.

38. The method of claim 37 wherein the sustained release composition elicits a C.sub.maxSS:C.sub.minSS ratio of 1.0 to 3.5 when administered b.i.d. or administered at 12-hour intervals to a human.

39. The method of claim 37 wherein said time period is twelve weeks.

40. The method of claim 37 wherein said sustained release composition is a tablet.

41. The method of claim 37 wherein the step of administering comprises b.i.d. administering or administering at 12-hour intervals.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.